Clinical trials for pediatric MS should be prioritized to test only one or two of the most promising agents - Commentary

Rogier Hintzen

Research output: Contribution to journalArticleAcademic

2 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)1653-1654
Number of pages2
JournalMultiple Sclerosis
Volume22
Issue number13
DOIs
Publication statusPublished - 2016

Cite this